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At the 2011 Yale Chemical Biology Symposium, Jason Gestwicki presented a novel yet in-
tuitive approach to drug screening. This method, which he termed “gray box” screening, tar-
gets protein complexes that have been reconstituted in vitro. Therefore, the gray box screen
can achieve greater phenotypic complexity than biochemical assays but avoids the need for
target identification that follows cell-based assays. Dr. Gestwicki’s research group was able
to use the gray box screen to identify myricetin as an inhibitor of the DnaK-DnaJ chaperone
complex. This review will discuss Dr. Gestwicki’s approach to identifying DnaK-DnaJ in-
hibitors as well as where the gray box screen fits among traditional techniques in drug dis-
covery.
IntroductIon
Biochemical  and  cell-based  screens
are two commonly practiced approaches in
drug discovery. Each technique has unique
advantages that make it amenable to differ-
ent situations. Biochemical screens facili-
tate the discovery of molecules that directly
target a protein of interest. However, bio-
chemical assays alone cannot define the
cellular phenotypes that result from a spe-
cific treatment. By contrast, cell-based as-
says  identify  effective  small  molecules
exclusively based on a cellular phenotype.
These assays are frequently termed “black
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tion is largely unknown. In his “gray box”
screening approach, Jason Gestwicki, Assis-
tant Professor of Pathology at the University
of Michigan, attempts to achieve a compro-
mise  between  the  biochemical  and  cell-
based assays. The gray box screen takes
advantage of the emergent properties of pro-
tein complexes. In this technique, multiple
components of a protein complex are puri-
fied and reconstituted in vitro. While only a
core enzyme in the complex has a measura-
ble activity, the supplemental components of
the complex lend a better approximation of
the complex’s function in vivo. Here, I will
review screening techniques as well as a
gray box screen developed by Lyra Chang
and  colleagues  in  the  Gestwicki  group,
which successfully identified the flavonoid
myricetin as an inhibitor of the DnaK-DnaJ
chaperone complex. 
BIochEmIcal ScrEEnS
Biochemical screens identify molecules
in an in vitro environment. The protein of in-
terest must be purified and requisite assays
must be performed to confirm the protein’s
activity. This technique relies on a specific
behavior of the protein as a read-out, such
as its ability to cleave substrates, hydrolyze
nucleotides, or modify protein targets with
a small molecule or peptide. For example,
screens for inhibitors of the molecular chap-
erone Hsp90 frequently target its ability to
hydrolyze ATP in order to power its protein
folding machinery [1]. Recently, increased
attention also has been given to small mole-
cule modulators of protein-protein interac-
tions [2]. Protein-protein interactions are
essential to many biological functions and
therefore represent a large class of targets for
screening [2]. A wide variety of methods can
be utilized to measure these activities, in-
cluding F￶rster resonance energy transfer
(FRET†)  and  fluorescence  polarization
[3,4,5]. After effective molecules are identi-
fied, they can be moved to cell-based assays.
Biochemical assays leave no question
about  the  target  and  reveal  more  details
about the mechanism of action of a molecule
than cell-based assays. Unfortunately, mol-
ecules that are active in vitro frequently lose
their effectiveness in the complex environ-
ment of the cell. Biochemical assays often
fail to predict how an interaction between a
molecule and a protein can be complicated
by a failure in delivery, toxicity, or a general
loss of activity. For example, molecules may
be processed in the cell or have its activity
modulated by the properties that arise from
unforeseen protein interactions. However,
molecules that cannot be used for therapeu-
tic purposes can still be effective probes for
protein function.
cEll-BaSEd ScrEEnS
The cell-based screen is a useful tech-
nique in the identification of novel therapeu-
tics because it incorporates the intracellular
environment into the assay. It accounts for
the presence of membranes and compart-
mentalization, as well as complex multi-pro-
tein  interactions.  These  assays  measure
phenotypic changes in response to treatment.
Common outputs include the activation or
inhibition of signaling pathways and also
protein interactions, which are often meas-
ured with the aid of reporters. Fluorescence
can be effective in determining changes in
protein activity and interactions. FRET is one
tool that has been utilized with relative suc-
cess [6]. For example, Yu et al. developed a
high-throughput screen (HTS) to identify
Hepatitis C virus (HCV) antivirals by em-
ploying an internally quenched peptide sub-
strate  of  the  HCV  NS3  protease  [7].
Bioluminescent reporters, such as luciferase,
have also been used in HTS [8].
Fluorescence and bioluminescence can
suffer from serious drawbacks. The modifi-
cation of proteins with fluorescent probes
can disrupt its function, and expression of
reporters may also interfere with normal cel-
lular behavior. Consequently, label-free ap-
proaches  are  often  preferable  when
available. Label-free methods are minimally
invasive and rely on inherent properties of
the cell, such as its morphology, adhesive-
ness,  and  proliferative  ability  [6]. While
these types of screens will require greater
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ber of techniques have been developed and
suggested for screening applications. For ex-
ample,  electric  cell-substrate  impedance
sensing (ECIS) is a potentially effective tool
in quantifying cell adhesiveness and mor-
phology [9].
Although cell-based assays measure the
activity and toxicity of molecules in biolog-
ically relevant conditions, they often reveal
little information about the target and mech-
anism of action. This adds an increased bur-
den of biochemical experiments after an
effective molecule is identified. Neverthe-
less, drug candidates have historically en-
tered  market  despite  a  poorly  elucidated
mechanism of action [10], as long as they
demonstrate low toxicity. This can unfortu-
nately result in undetected side effects that
become apparent only after the drug has
reached market.  
‘GraY Box’ ScrEEnInG
In a gray box screen, a protein complex
is purified and reconstituted in a biochemi-
cal environment. The complex is then used
to specifically screen for molecules that tar-
get the emergent properties that arise only
when the complex is formed. Ideally, only
one core enzyme possesses a measureable
activity, while the accessory proteins modu-
late this activity. The gray box approach ex-
ploits features of both previously discussed
approaches by providing a more physiolog-
ically relevant environment than the bio-
chemical screen but reducing the need for
additional assays to determine the target of
effective molecules.
Lyra Chang and colleagues from the
Gestwicki group coined the term “gray box”
screening to define their approach in identi-
fying inhibitors of the DnaK-DnaJ complex
[11].  The  molecular  chaperone  DnaK,  a
member of the Heat Shock Protein 70 kDa
family (Hsp70), plays an essential role in
protein homeostasis in Escherichia coli [12].
DnaK consists of a 41 kDa nucleotide-bind-
ing domain (NBD) and a 26 kDa substrate-
binding domain (SBD) [13]. The NBD is
itself made up of four subdomains, IA, IIA,
IB, and IIB, which form an ATP-binding
cleft [14]. The NBD is responsible for hy-
drolyzing ATP, thereby providing energy for
the chaperone machinery. DnaJ, a member
of  the  Hsp40  family,  is  a  co-chaperone
which binds to the IA and IIA subdomains
of DnaK [15]. This interaction stimulates the
ATPase activity of DnaK. In an ADP-bound
form, DnaK binds tightly to its protein sub-
strate, but loses this affinity when ADP is re-
placed by ATP [16].
Chang et al. purified DnaK and DnaJ
and established a high-throughput ATPase
assay for DnaK that utilizes the inorganic
phosphate chelator malachite green as a re-
porter [17]. In their current work, they com-
bined DnaK and DnaJ in an optimized ratio
and screened for inhibitors at high concen-
trations of ATP to limit the discovery of nu-
cleotide competitive inhibitors. They then
screened through a collection of extracts
from 36 commercial spices and crude plant
materials.  Chang  et  al.  justified  this  ap-
proach  citing  the  well-defined  chemical
components of these materials and also a
motivation  to  determine  whether  natural
products produced by plants could inhibit
Hsp70-Hsp40 family members, commonly
found in plant pathogens. They identified six
extracts (allspice, black tea, cocoa, cinna-
mon, cloves, and white tea) that inhibited
ATPase activity by greater than 30 percent.
Chang et al. proceeded to isolate and con-
firm epicatechin-3-gallate (ECG), a member
of the flavonoid family, as the major active
component in white tea.  
Based on this evidence, the Gestwicki
group studied the structure-activity relation-
ships (SARs) of flavonoids on the DnaK-
DnaJ  complex  and  ultimately  identified
myricetin as the most effective inhibitor of
DnaK ATPase activity among flavonoids.
Through extensive structural biology stud-
ies, they discovered that myricetin does not
competitively inhibit ATP or DnaJ binding
but instead binds to the IB and IIB subdo-
mains of DnaK. In fact, they showed that
myricetin has no effect on the intrinsic AT-
Pase activity of DnaK. Furthermore, they
demonstrated that myricetin can bind to the
subdomains only when ATP-binding causes
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action prevents contacts between DnaK and
DnaJ allosterically, thereby reducing DnaJ’s
ability to stimulate ATPase activity. 
The power of this screen lies in its abil-
ity to identify molecules that modulate an
emergent  property  that  is  only  apparent
through the formation of a protein complex
between DnaK and DnaJ. Because their out-
put is the signal that arises from the co-stim-
ulatory  effect  of  DnaJ,  their  screen  is
designed to specifically identify molecules
that disrupt its interaction with DnaK. Not
surprisingly, they identify a molecule that
exerts an effect on enhanced ATPase activity
allosterically to the NBD. An essential cri-
terion to their approach is to use high con-
centrations  of ATP,  thereby  reducing  the
possibility  of  identifying  competitive  in-
hibitors. This is important because the high
concentrations of intracellular ATP make the
development of a competitive inhibitor more
difficult. Therefore, Chang et al. have de-
veloped a screen that can identify inhibitors
that might have otherwise gone undetected
by alternative screening techniques.
Nevertheless, the gray box screen can
suffer from drawbacks similar to the bio-
chemical screen. Like biochemical assays,
the gray box method is contingent on an ini-
tial understanding of a protein’s activity. Of
course, this requires the purification of the
protein of interest and its accessory proteins
followed by in vitro reconstitution as well as
assays to characterize its activities. While
DnaK and DnaJ form a relatively simple
two-component complex, purification and
reconstitution of some larger complexes is
hardly a trivial task. Moreover, the gray box
method may be unfeasible if the phenotypic
complexity of the reconstituted system is too
great. Chang et al. were able to focus on one
output and one modulator, but other com-
plexes may have multiple activities. Finally,
the gray box is ultimately still a biochemical
environment and therefore may not be the
most efficient screen for therapeutics. Mol-
ecules discovered in a gray box will still
need to be moved to a cell-based assay to
gain a greater understanding of its activity
and toxicity in vivo.
concluSIon
Chang et al. identified and character-
ized myricetin as an inhibitor of the DnaK-
DnaJ  interaction,  demonstrating  that  the
gray box method can be a viable screening
approach. They then suggested that it could
be an appropriate method of studying Hsp70
members, as well as other proteins that are
regulated by multiple accessory proteins,
particularly  molecular  chaperones.  They
recognized that this approach may be less ef-
fective in studying systems that are difficult
to reconstitute in vitro or that demonstrate
exceedingly complex phenotypes. Conse-
quently, a fairly exhaustive understanding of
the complex of interest is necessary before a
gray box screen can be applied, as the screen
is not appropriate for all situations. Nonethe-
less, the Gestwicki group has high expecta-
tions for this approach, anticipating that it
might soon be used to study multi-protein
systems like the mTor complex, chromatin-
remodeling  complexes,  and  the  exocyst.
These studies are certainly not beyond the
realm of possibility. The gray box screen has
the potential to be useful as both a tool to
study protein function and as one to identify
drug candidates.
rEfErEncES
1. Avila C, Kornilayev BA, Blagg BS. Devel-
opment and optimization of a useful assay for
determining Hsp90's inherent ATPase activ-
ity. Bioorg Med Chem. 2006;14(4):1134-42.
2. Arkin MR, Wells JA. Small-molecules in-
hibitors of protein-protein interactions: pro-
gressing towards the dream. Nat Rev Drug
Discov. 2004;3(4):301-17.
3. Sch￤ferling M, Nagl S. F￶rster resonance en-
ergy transfer methods for quantification of
protein-protein interactions on microarrays.
Methods Mol Biol. 2011;723:303-20.
4. Smith DS, Eremin SA. Fluorescence polar-
ization immunoassays and related methods
for  simple,  high-throughput  screening  of
small  molecules.  Anal  Bioanal  Chem.
2008;391(5):1499-507.
5. Owicki JC. Fluorescence polarization and
anisotropy in high throughput screening: per-
spectives  and  primer.  J  Biomol  Screen.
2000;5(5):297-306.
6. Michelini  E,  Cevenini  L,  Mezzanotte  L,
Coppa A, Roda A. Cell-based assays: fuelling
drug  discovery.  Anal  Bioanal  Chem.
2010;398(1):227-38.
494 Wong: Targeting emergent properties of protein complexes7. Yu X, Sainz B Jr, Uprichard SL. Develop-
ment of a cell-based hepatitis C virus infec-
tion fluorescent resonance energy transfer
assay  for  high-throughput  antiviral  com-
pound  screening.  Antimicrob  Agents
Chemother. 2009;53(10):4311-9.
8. Thorne N, Inglese J, Auld DS. Illuminating
insights into firefly luciferase and other bio-
luminescent reporters used in chemical biol-
ogy. Chem Biol. 2010;17(6):646-57.
9. Wegener J, Keese CR, Giaever I. Electric
cell-substrate impedance sensing (ECIS) as a
noninvasive means to monitor the kinetics of
cell spreading to artificial surfaces. Exp Cell
Res. 2000;259(1):158-66.
10. Imming P, Sinning C, Meyer A. Drugs, their
targets and the nature and number of drug tar-
gets. Nat Rev Drug Discov. 2006;5(10):821-
34.
11. Chang L, Miyata Y, Ung PM, Bertelsen EB,
McQuade TJ, Carlson HA, et al. Chemical
screens against a reconstituted multiprotein
complex: myricetin blocks DnaJ regulation
of DnaK through an allosteric mechanism.
Chem Biol. 2011;18(2):210-21.
12. Mayer MP, Bukau B. Hsp70 chaperones: cel-
lular functions and molecular mechanism.
Cell Mol Life Sci. 2005;62(6):670-84.
13. Zhu X, Zhao X, Burkholder WF, Gragerov A,
Ogata CM, Gottesman ME, et al. Structural
analysis of substrate binding by the molecu-
lar  chaperone  DnaK.  Science.
1996;272(5268):1606-14.
14. Harrison CJ, Hayer-Hartl M, Di Liberto M,
Hartl F, Kuriyan J. Crystal structure of the
nucleotide exchange factor GrpE bound to
the ATPase domain of the molecular chaper-
one DnaK. Science. 1997;276(5311):431-5.
15. Suh WC, Burkholder WF, Lu CZ, Zhao X,
Gottesman ME, Gross CA. Interaction of the
Hsp70 molecular chaperone, DnaK, with its
cochaperone DnaJ. Proc Natl Acad Sci USA.
1998;95(26):15223-8.
16. Buchberger A, Theyssen H, Schr￶der H, Mc-
Carty JS, Virgallita G, Milkereit P, et al. Nu-
cleotide-induced conformational changes in
the ATPase and substrate binding domains of
the DnaK chaperone provide evidence for in-
terdomain  communication.  J  Biol  Chem.
1995;270(28):16903-10.
17. Chang L, Bertelsen EB, Wis￩n S, Larsen EM,
Zuiderweg ER, Gestwicki JE. High-through-
put screen for small molecules that modulate
the ATPase activity of the molecular chaper-
one DnaK. Anal Biochem. 2008;372(2):167-
76.
495 Wong: Targeting emergent properties of protein complexes